معلومات عن هذه الحلقة
Sepul Bio recently announced that it completed enrollment of its Phase 2b safety and efficacy clinical trial for ultevursen – an investigational RNA therapy to treat patients who have retinitis pigmentosa (RP) associated with mutations in the USH2A gene.
الإنجليزية
الولايات المتحدة
النص 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
البحث في الحلقات الماضية
البحث في الحلقات السابقة من Foundation Fighting Blindness.
حلقات أخرى في هذا البودكاست
Tarsus Pharmaceuticals announced plans to acquire Alkeus Pharmaceuticals, including its emerging oral treatment for Stargardt disease, gildeuretinol (ALK-001), in a deal valued up to $800 million. Stargardt disease is the most common form of inherited macular degeneration and is often diagnosed in …
Dr. Alicia Kemble explains how the Foundation is using venture philanthropy to drive treatments for inherited retinal diseases even closer to the finish line.
Belite Bio’s tinlarebant could become the first-ever approved treatment for Stargardt disease
In Europe, Science Corporation has commercially launched PRIMA, a retinal implant designed to restore central vision in people with geographic atrophy (GA). The treatment has been shown in clinical trials to restore functional central vision in people with GA who until now had no way to get lost ce…
إخلاء المسؤولية: البودكاست والأعمال الفنية المضمنة في هذه الصفحة مأخوذة من Foundation Fighting Blindness، وهي مملوكة لمالكها وليست تابعة لشركة Listen Notes, Inc أو معتمدة منها.
تعديل
شكراً على مساعدتنا في الحفاظ على قاعدة بيانات البودكاست مُحدَّثة.
